MERLIN will present at EU-MSC2 meeting in Leiden in September

Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTARREACHRETHRIM, Stellar, MERLINNephstromSCIENCEVISICORT and Adipoa-2AUTOSTEMBOOSTB4, SEPCELL, RESSTORE, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms of action and potency assays; an interactive panel discussion on product development, and product development and market authorisation in a changing regulatory landscape.

The objectives of the meeting are to:

  • Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
  • Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
  • Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
  • Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

Expected impacts and outcomes:

  • Provide opportunities to develop new mesenchymal stromal cell networks
  • Disseminate the findings and challenges between MSC-focussed consortia
  • Improve the communication potential of research, outcomes and the value of the research
  • Explore potential for new commercial technologies
  • Collectively enhance the quality and impact of planned clinical trials

These EU-funded projects are:

  • Improving the quality of life for European citizens
  • Progressing the clinical translation of MSC research and developments

For more information, please visit EU MSC2 2017.
Register via Eventbrite by August 14 2017.
Read the EU-MSC2 2015 meeting report here.

Interview with Prof. Viola of UNIPD

Prof. Antonella Viola has been interviewed by Italian broadcaster TG1, following her return to Padova. In this interview, she talks about a research project investigating the correlation among inflammation and cancer. In Padova, Prof. Viola leads a group of eight researchers working on different projects with the aim of designing novel personalized therapy against inflammation-related diseases. The role of her team in the MERLIN project is to investigate the mechanism of action of Mesenchymal Stromal Cells (MSC) in dampening liver inflammation.


 

AV Interview TG1

EMC talk about their work on the MERLIN project

erasmus

MERLIN partners Erasmus MC are studying the interaction between stem cells and the immune system and in their laboratory they are trying to improve the quality of the stem cells.

Check out this video, where you can learn more about the EMC team, their lab, and their work on the MERLIN project.

 

EU MSC2 2015: Contributing to MSC Knowledge-Sharing, Research & Development

Our sister project REDDSTAR and Leiden University Medical Center are co-organizing EU MSC2 2015, a meeting in Leiden, NL on September 7th and 8th to bring together nine EU-funded, mesenchymal stromal cell-focussed consortia. Projects include: REDDSTAR, REACH, RETHRIM, Stellar, MERLIN, Nephstrom, SCIENCE, VISICORT and Adipoa-2. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden.

The objectives of the meeting are to:

  • Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
  • Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
  • Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
  • Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

 

Expected impacts and outcomes:

  • Provide opportunities to develop new mesenchymal stromal cell networks
  • Disseminate the findings and challenges between MSC-focussed consortia
  • Improve the communication potential of research, outcomes and the value of the research
  • Explore potential for new commercial technologies
  • Collectively enhance the quality and impact of planned clinical trials

These EU projects are:

  • Boosting human capital: 20-30 positions created
  • Improving the quality of life for European citizens
  • Progressing the clinical translation of MSC research and developments

 

For more information, please visit EU MSC2 2015 and register via Eventbrite.

For queries: LeidenRM@gmail.com

Danielle Nicholson, Orbsen Therapeutics, NUI Galway and Brigitte Wieles, Project Manager LUMC

MERLIN covered on PSC Website

MERLIN recently received coverage on the Primary Sclerosing Cholangitis Support website.

PSC Support is

the UK charity dedicated to helping people affected by Primary Sclerosing Cholangitis (PSC). PSC Support is run by a small team of volunteers, totally funded from charitable donations, and here to help anyone affected by Primary Sclerosing Cholangitis.

Our objectives are to:

  • provide information and support to those affected by PSC.
  • work with partners to promote awareness of PSC, current research and the need for organ donation.
  • support PSC-related medical practitioners and researchers by:
    • giving PSC patients access to the latest relevant medical information to promote patient participation in essential trials;
    • providing grants towards projects that have specific target outcomes.
  • develop effective partnerships between PSC Support and medical practitioners, researchers, policy makers and people affected by PSC.

You can find out more about their organisation here.

MERLIN introduced at ISCT 2014

Project Partner Orbsen Therapeutics presented at the ISCT Paris Conference on April 22nd 2014, in a session entitled “EU funded projects in Cell Therapy”.

Read more

Coverage in The Irish Times

The Irish Times covered the MERLIN Project on April 22nd, 2014, in an article titled “Orbsen Therapeutics to take part in €6m liver disease clinical trial.”

Article Abstract:

Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (Remedi) has announced plans to partner with the University of Birmingham in a €6 million project to fight liver disease.

The stem cell research company, which was founded by Prof Frank Barry and Prof Tom O’Brien in 2006, will collaborate with the university on an EU FP7-funded project known by as Merlin (MEsynchymal stem cells to Reduce Liver INflammation). The project, which is led by Prof Phil Newsome, will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial.

Please read the rest of the article here.

MERLIN Kickoff Meeting

MERLIN partners meet in Birmingham, UK, on 10-11 February, 2014 to initiate the project.

Read more

MERLIN Project Website Launched

The MERLIN project website is now launched. This website will support individuals trying to find out more about the project, and will provide both the public and other researchers with information about our plans, hypotheses, work and results.

Read more